Latest "Placebo Hepatitis Virus Infection" News Stories

04:13 EDT 26th April 2015 | BioPortfolio

Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.

More Information about Placebo Hepatitis Virus Infection on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.

Showing "Placebo Hepatitis Virus Infection" News Articles 1–25 of 8,200+

Extremely Relevant

Hepatitis C and HIV Co-infection Closing the Gaps

Hepatitis C virus (HCV) infection causes substantial morbidity and mortality, but patients with human immunodeficiency virus (HIV) co-infection are 3 times more likely to develop cirrhosis or liver decompensation than those infected with hepatitis C ...

Hepatitis B Virus exposure matures infants' immune systems

Hepatitis B Virus Infection (HBV) exposure increases the immune system maturation of infants, which may give a better survival advantage to counteract bacterial infection during early life. These findings radically modify the way that HBV vertical in...

[Review] Resistance to hepatitis C virus: potential genetic and immunological determinants

Studies of individuals who were highly exposed but seronegative (HESN) for HIV infection led to the discovery that homozygosity for the Δ32 deletion mutation in the CCR5 gene prevents viral entry into target cells, and is associated with resistance ...

Age-related hepatitis B infection and the gut microbiome

(Medical Xpress)—The hepatitis B virus (HBV), which affects the liver, behaves differently in different people depending on genetics and the age the person is when infected. Ninety-five percent of adults who contract hepatitis B clear the virus aft...

Study builds understanding of hepatitis C virus replication

Hepatitis C virus infection is a common cause of liver disease and of liver cancer in the United States. Through a new study that explores one aspect of how the virus hijacks host cell machinery to replicate itself, UNC Lineberger Comprehensive Cance...

Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus

The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that will likely change the HCV treatment paradigm. However, the effectiveness of these new drugs c...

Alcohol use disorders - stronger predictor of mortality than chronic hepatitis C virus infection

(European Association for the Study of the Liver) Results presented today at The International Liver Congress™ 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general popula...

Hepatitis C and its impact on renal transplantation

Hepatitis C virus (HCV) infection imposes a substantial economic, clinical, and societal burden worldwide. In this Review, Morales and Fabrizi compare the treatment options that are available to patients with HCV infection, before and after renal tra...

Genes show the way to better treatment of hepatitis A

One of the most common causes of hepatitis A (formerly known as infectious hepatitis) is a hepatitis C virus infection in the liver. The disease can be treated medically, but not all patients are cured by the treatment currently available. New resear...

Life expectancy among patients with chronic hepatitis C virus infection and cirrhosis

Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did not attain SVR had reduced su...

Genes show the way to better treatment of hepatitis C

(Aarhus University) One of the most common causes of hepatitis C (formerly known as infectious hepatitis) is a hepatitis C virus infection in the liver. The disease can be treated medically, but not all patients are cured by the treatment currently a...

Viekirax and Exviera for the Treatment of Chronic Hepatitis C Virus Infection

Viekirax (ombitasvir / paritaprevir / ritonavir) and Exviera (dasabuvir) is indicated for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection and compensated cirrhosis.

BMS awards nine new grants to fight against hepatitis B and C in China and India

The Bristol-Myers Squibb Foundation has announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by focusing on the most vuln...

[News] Possible link between hepatitis B infection and gastric cancer

Hepatitis B virus (HBV) infection might increase the risk of developing gastric cancer, according to the results of a new study.

Latest advances in hepatitis C therapy

The availability of new protease inhibitors is revolutionising the treatment of hepatitis C virus infection.

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody

Inhibiting virus cell entry by targeting tight junctions cures HCV infection in mice.

Widespread hepatitis C screening may result in more harms than benefits

Several organizations have recommended scaling up screening for hepatitis C infection. But experts warn that no study has tested whether this will lead to net clinical benefit or harm. Hepatitis C is a virus that can infect and damage the liver.

Enanta reports results from TURQUOISE-I study in chronic hepatitis C patients with HIV-1 co-infection

Enanta Pharmaceuticals, a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced at The Liver Meeting 2014 results from studies in chronic hepatitis C virus (HCV) p...

Hepatitis A hospitalization rate declines in U.S.

The rate of hospitalization due to hepatitis A virus (HAV) infection has significantly declined in the U.S. from 2002 to 2011, new research shows. Findings show that older patients and those with chronic liver disease are most likely to be hospitaliz...

Study Details MicroRNA's Role as a Double Agent During Hepatitis C Infection

In the battle between a cell and a virus, either side may resort to subterfuge. Molecular messages, which control the cellular machinery both sides need, are vulnerable to interception or forgery. New research at Rockefeller University has revealed the unique twist on just such a strategy deployed by the liver-infecting hepatitis C virus –

HBV exposure matures infants' immune systems

A Singapore led study has shown that Hepatitis B Virus Infection (HBV) exposure increases the immune system maturation of infants, which may give a better survival advantage to counteract bacterial infection during early life. These findings radicall...

NIH Study Suggests Alternative Drug to Treat Hepatitis C Virus Infection

An over-the-counter drug indicated to treat allergy symptoms limited hepatitis C virus activity in infected mice, according to a National Institutes of Health study. The results suggest that the drug, chlorcyclizine HCl (CCZ), potentially could be used to treat the virus in people. Results were published April 8 in Science Translational Medicine.

Hepatitis B Virus May Be Linked to Gastric Cancer

Hepatitis B virus (HBV) infection is associated with gastric cancer, particularly in patients without a family history of gastric cancer, researchers from China report. Reuters Health Information

Harvoni will keep Gilead atop Hepatitis C virus treatment landscape, says GlobalData Analyst

The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company to mai...

GlobalData Analyst: Harvoni Will Keep Gilead Atop Hepatitis C Virus Treatment Landscape

The recent US Food and Drug Administration (FDA) approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company ...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks